D-Luciferin sodium salt

製品コードS6924 バッチS692403

印刷

化学情報

Synonyms

D-(-)-Luciferin sodium salt, Firefly luciferin sodium salt

Storage
(From the date of receipt)

3 years -20°C(in the dark) powder

化学式

C₁₁H₇N₂NaO₃S₂

分子量

302.3

CAS No.

103404-75-7

Solubility (25°C)*

体外

Water

50 mg/mL (165.39 mM)

DMSO

20 mg/mL (66.15 mM)

Ethanol

Insoluble

体内（毎回新しく調製した物を用意してください）

Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。	1.000mg/ml (3.31mM)	Taking the 1 mL working solution as an example, add 50 μL of 20 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。	0.300mg/ml (0.99mM)	Taking the 1 mL working solution as an example, add 50 μL of 6 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	D-Luciferin sodium saltは、生物発光性昆虫において光の生成を触媒するルシフェラーゼの天然基質です。
in vitro	1.Example protocol for in vitro bioluminescent image assays a) Prepare a 100 mM (100-200X) Luciferin stock solution in sterile water. Mix well. Use immediately, or make single use aliquots, and store at -20℃, avoid freeze-thaw cycles, avoid exposure to the light. b) Prepare a 0.5-1 mM working solution of D-Luciferin in pre-warmed tissue culture medium. c) Aspirate media from cultured cells. d) Add Luciferin working solution to cells, and incubate the cells for 5-10 minutes at 37℃ just prior to imaging. 2.Example protocol for in vivo bioluminescent image assays a) Prepare a 15 mg/mL Luciferin stock solution in DPBS, without Mg2+ and Ca2+. Mix well. b) Filter sterilizes the solution through a 0.2 μm filter. Use immediately, or make single use aliquots, and store at -20℃, avoid freeze-thaw cycles, avoid exposure to the light. c) Inject the luciferin intra-peritoneally (i.p.) 10-15 minutes before imaging at 150 mg/kg (or 10 μL/g of luciferin stock solution) of the animal body weight. Note: A kinetic study of luciferin should be performed for each animal model to determine peak signal time. 3.Example protocol for luciferin reporter assays a) Prepare a 100 mM Luciferin stock solution in sterile water. Use immediately, or make single use aliquots, and store at -20℃, avoid freeze-thaw cycles, avoid exposure to the light. b) Prepare a 1 mM working solution of D-Luciferin with 3 mM ATP, 1 mM DTT and 15 mM MgSO4 in 25 mM tricine buffer pH 7.8. c) Pipette 5-10 μLof cell lysate into a microplate. Use lysis reagent or buffer without lysate as a blank. d) Prime luminometer with luciferin working solution. e) Inject 200 μL of luciferin working solution with no delay and a 10 second integration time.

製品説明

D-Luciferin sodium saltは、生物発光性昆虫において光の生成を触媒するルシフェラーゼの天然基質です。

in vitro

1.Example protocol for in vitro bioluminescent image assays
a) Prepare a 100 mM (100-200X) Luciferin stock solution in sterile water. Mix well. Use immediately, or make single use aliquots, and store at -20℃, avoid freeze-thaw cycles, avoid exposure to the light.
b) Prepare a 0.5-1 mM working solution of D-Luciferin in pre-warmed tissue culture medium.
c) Aspirate media from cultured cells.
d) Add Luciferin working solution to cells, and incubate the cells for 5-10 minutes at 37℃ just prior to imaging.
2.Example protocol for in vivo bioluminescent image assays
a) Prepare a 15 mg/mL Luciferin stock solution in DPBS, without Mg2+ and Ca2+. Mix well.
b) Filter sterilizes the solution through a 0.2 μm filter. Use immediately, or make single use aliquots, and store at -20℃, avoid freeze-thaw cycles, avoid exposure to the light.
c) Inject the luciferin intra-peritoneally (i.p.) 10-15 minutes before imaging at 150 mg/kg (or 10 μL/g of luciferin stock solution) of the animal body weight.
Note: A kinetic study of luciferin should be performed for each animal model to determine peak signal time.
3.Example protocol for luciferin reporter assays
a) Prepare a 100 mM Luciferin stock solution in sterile water. Use immediately, or make single use aliquots, and store at -20℃, avoid freeze-thaw cycles, avoid exposure to the light.
b) Prepare a 1 mM working solution of D-Luciferin with 3 mM ATP, 1 mM DTT and 15 mM MgSO4 in 25 mM tricine buffer pH 7.8.
c) Pipette 5-10 μLof cell lysate into a microplate. Use lysis reagent or buffer without lysate as a blank.
d) Prime luminometer with luciferin working solution.
e) Inject 200 μL of luciferin working solution with no delay and a 10 second integration time.

プロトコル(参考用のみ)

参考

https://newsletter.arkat-usa.org/get-file/29712/

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation [ Nat Commun, 2023, 14(1):265]	PubMed: 36650153
Carbenoxolone disodium suppresses the migration of gastric cancer by targeting HDAC6 [ Future Med Chem, 2023, 15(4):333-344]	PubMed: 36946221
A magneto-controlled biocatalytic cascade with a fluorescent output [ Org Biomol Chem, 2022, 20(9):1869-1873]	PubMed: 35156979
Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy [ Breast Cancer Res, 2021, 23(1):11]	PubMed: 33485378
KDM4A-mediated histone demethylation of SLC7A11 inhibits cell ferroptosis in osteosarcoma [ Biochem Biophys Res Commun, 2021, 550:77-83]	PubMed: 33689883
Tumor treating fields increases membrane permeability in glioblastoma cells [ Cell Death Discov, 2018, 4:113]	PubMed: 30534421

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。